Jessica Fye
Stock Analyst at JP Morgan
(4.47)
# 286
Out of 5,182 analysts
216
Total ratings
61.76%
Success rate
14.85%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $16.88 | +77.73% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $19.23 | +35.21% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $34.33 | -27.18% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $10.58 | +117.39% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $194.20 | +2.47% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $67.82 | -4.16% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $50.96 | -50.94% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $95.50 | +25.65% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $322.11 | +46.84% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $18.16 | +318.50% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $96.07 | -7.36% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $54.53 | +118.23% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $239.28 | +10.33% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $436.27 | +21.48% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $309.66 | +24.33% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $75.17 | +6.43% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $39.44 | +31.85% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $95.20 | -19.12% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $33.36 | +4.92% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $154.81 | -12.80% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $571.73 | -42.28% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $9.56 | +35.98% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $31.05 | +61.03% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $31.00 | -3.23% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $77.50 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $7.96 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.17 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.48 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.92 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.72 | +306.98% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.12 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.11 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $16.88
Upside: +77.73%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $19.23
Upside: +35.21%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $34.33
Upside: -27.18%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $10.58
Upside: +117.39%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $194.20
Upside: +2.47%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $67.82
Upside: -4.16%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $50.96
Upside: -50.94%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $95.50
Upside: +25.65%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $322.11
Upside: +46.84%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $18.16
Upside: +318.50%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $96.07
Upside: -7.36%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $54.53
Upside: +118.23%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $239.28
Upside: +10.33%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $436.27
Upside: +21.48%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $309.66
Upside: +24.33%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $75.17
Upside: +6.43%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $39.44
Upside: +31.85%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $95.20
Upside: -19.12%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $33.36
Upside: +4.92%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $154.81
Upside: -12.80%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $571.73
Upside: -42.28%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.56
Upside: +35.98%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $31.05
Upside: +61.03%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $31.00
Upside: -3.23%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $77.50
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $7.96
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.17
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.48
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.92
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.72
Upside: +306.98%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.12
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.11
Upside: -